Compare AADX & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AADX | BEAM |
|---|---|---|
| Founded | 1900 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.6B |
| IPO Year | 2026 | 2019 |
| Metric | AADX | BEAM |
|---|---|---|
| Price | $9.90 | $24.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | $22.88 | ★ $52.15 |
| AVG Volume (30 Days) | ★ 1.9M | 1.5M |
| Earning Date | 11-11-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | $36.93 | N/A |
| Revenue Next Year | $15.57 | $29.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $10.31 | $20.23 |
| 52 Week High | $24.24 | $38.26 |
| Indicator | AADX | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 33.00 | 46.76 |
| Support Level | N/A | $24.30 |
| Resistance Level | $13.03 | $26.72 |
| Average True Range (ATR) | 0.75 | 1.30 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 6.98 | 33.33 |
Applied Aerospace & Defense Inc specializes in providing engineering and vertically integrated manufacturing solutions for space and defense technology companies. The company builds complex hardware for extreme operating environments, combining deep material science and IP-enabled process expertise with the ability to enable rapid prototyping, enhance new product development, and responsively scale production. The majority of the company's revenue is derived from the sales of Defense Aviation and Airborne Systems, followed by Space and Launch Systems, C5ISR and Precision Strike Systems.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.